Skip to content

Cannabidiol Medication Intervention Trial (CALM-IT)

Alzheimer’s Disease

Agitation is common in patients with Alzheimer's Disease (AD) and is one of the most distressing and symptoms of AD. Agitation is associated with faster loss of independent living, increased caregiver stress, poorer quality of life, and increased risk of death. In addition, current treatments show only mild benefits but come with side effects. Therefore, identifying safer and more effective treatments for agitation in AD is a priority.

null

Participation Requirements

  • Sex:

    Male, Female, Intersex

  • Eligible Ages:

    55 and up

Participation Criteria

Inclusion Criteria:
1. Diagnosis of Alzheimer's disease
2. Significant agitation
3. 55 years or older
4. Availability of a caregiver that can participate along with the participant
Exclusion Criteria:
1. Allergies to cannabis and cannabis products.
2. Presence of significant delusions and/or hallucinations.
3. Major depression.

Study Location

University of Calgary
University of Calgary
Calgary, Alberta
Canada

Contact Study Team

Study Sponsored By
University of Calgary
Participants Required
More Information
Study ID: REB24-0702